I won't pick bones about it. Yesterday was a tough day when Inovio announced there is a technical hold on the expected INO4800 Phase 2/3 trials. The reason is FDA questions on the Cellectra device used to help deliver the vaccine. It is NOT about any adverse effects of patients in the Phase 1 trial.
One philosophy I try to maintain is the "Some" plan not "too much". I try to pursue a company that may be under - recognized but have some aspects showing much deeper value than on the surface. I believe Inovio is one such company. The technical hold is "a hiccup" as one investment analyst called it but not a show stopper.
That said we are only human and Inovio stock has challenged the very depths of many shareholders belief and some their hearts and souls over the past few months. The sell off was pretty rough at the very time we were set up to expect the go ahead for Inovio's phase 3 clinical trial against C19 and the mutant variant that is showing up. The shorts won a battle (again). I want to roar and win the war though! The best vaccine may be INO4800 in my view, the Inovio cancer treatment pipeline and hope keep me in some INO today.
I will say how I traded it as of this post. I got so discouraged that I painfully sold half my INO shares yesterday. In Inovio's PR, I did not see the sense of urgency when they wrote a reply will be made "in October" and the FDA has 30 days to reply. I guess I held "too much" because although I was feeling cautious, the Inovio CEO was so confident about the new Phase and subsequent funding.
So today, I am still holding some INO (and watching) because I still believe that INO4800 could well be THE BEST vaccine to protect against C-19. From surveying the other's, INO4800 is the ONLY vaccine I would personally take. We are in a Pandemic! So I ask where is Pence who heads up the OWS team? I believe that the FDA hold on INO4800 is irresponsible in this Pandemic. That FDA hold is even shaking my independent view as to if I will vote for Trump/ Pence. I will not vote for Biden because , for one, of who backs him, socialists and Marxists. At same time , I will not vote for morons either whom I do not believe are paying proper attention to the details of this Pandemic. I am on the fence with Trump/ Pence as of this post. However, there is some buzz going on about the administration possibly favoring Sorrento (SRNE). Good mojo?
In summary , I sold some INO on recent bad juju.
I am holding some INO on INO4800 and the pipeline and hope.
I bought some SRNE on broad approaches and positive mojo.
Holding Dry Powder
watching!
______
I believe in this market, holding a fair amount of cash or "dry powder" is prudent. With the above said, as a trader I am watching another company and have taken a new small position. Below are a few PRs on SRNE. If interested, scroll down and take a look at what is in bold type.
Sorrento Therapeutics Says Preclinical Data Show Potential of Coronavirus-Neutralizing Antibodies
10:45 AM EDT, 09/29/2020 (MT Newswires) -- Sorrento Therapeutics (SRNE) reported late Monday positive results from preclinical studies on animals, which showed the neutralizing effects of COVI-Guard and COVI-AMG antibodies against SARS-CoV-2, the virus that causes COVID-19.
Both antibodies have shown 100% in vitro neutralization of SARS-CoV-2 at concentrations of 6 ug/ml and 78 ng/ml, respectively, the firm said. They have also shown protective abilities against the emerging Spike D614G variant virus.
The company has already received clearance from the US Food and Drug Administration for a phase 1 clinical trial of STI-1499 in hospitalized COVID-19 patients, it said. It plans to file an investigational new drug application for STI-2020 "as soon as possible."
Shares were 7.7% higher in recent trading.
Price: 10.93, Change: +0.78, Percent Change: +7.68
Sorrento Therapeutics Reports Positive Results of Drug Used to Reduce Osteoarthritis Knee Pain
09:47 AM EDT, 09/28/2020 (MT Newswires) -- Sorrento Therapeutics (SRNE) said Monday results of a phase 1b trial of resiniferatoxin, a drug used to treat osteoarthritis knee pain, showed no dose-limiting toxicities in the patients dosed with the drug candidate at any dose level studied.
The study confirmed the clinical potential of the drug for long-term control of osteoarthritis knee pain, the company said. The dose of 12.5ug was selected as the likely optimal therapeutic dose for future clinical trials. The study is scheduled to complete the last patient follow-up in 1Q 2021.
The company said it would move the investigational drug product into a phase 2 clinical trial, expected to start this year and a subsequent phase 3 clinical trial expected to start in 2021.
__
ALL in my humble opinion, scroll down and read more..
This site does NOT make Buy / Sell recommendations.
